Oncolytics Biotech submits Orphan Designation to EMA for treatment of ovarian, pancreatic cancers

Download PDF Copy

Dec 22 2014

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced that it has submitted applications for Orphan Designation to the European Medicines Agency ("EMA") for REOLYSIN^® for the treatment of pancreatic and ovarian cancers.

"This is the second jurisdiction in which we have elected to file for Orphan Designation," said Dr. Brad Thompson, President and CEO of Oncolytics. "The EMA serves all 28 member countries of the EU and securing Orphan Designation would help support the future development of REOLYSIN^® in the region."

Source:

Oncolytics Biotech Inc.

Posted in: Drug Trial News | Medical Condition News

Comments (0)

Download PDF Copy

Suggested Reading

Persistent COVID-19 in the intestines may drive inflammation in cancer patients

RAB26 identified as a critical regulator of prostate cancer aggressiveness

Repurposed diabetes drugs boost CAR T therapy effectiveness in bladder cancer

Targeting telomere damage offers new path to boost cancer immunotherapy

PM2.5 pollution linked to lung cancer shows sharp declines in the U.S. but not in China

Scientists find a smarter way to activate the immune system against cancer

New method reveals how mitochondrial DNA mutations influence cancer growth

Lung tumors rewire immune cells in the bone marrow before they reach cancer sites

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.